PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsLeuprolide acetate
Leuprolide acetate
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
496 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C6127129681230251
Breast neoplasmsD001943EFO_0003869C50324182752
EndometriosisD004715EFO_0001065N801864726
Precocious pubertyD011629—E22.82—78421
InfertilityD007246EFO_0000545—3—26920
LeiomyomaD007889—D251344213
RecurrenceD012008———261110
MyofibromaD047708——123229
Polycystic ovary syndromeD011085EFO_0000660E28.211—338
AdenomyosisD062788EFO_1001757N80.0———314
Show 32 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230——4238—436
NeoplasmsD009369—C80187—116
ObesityD009765EFO_0001073E66.92—1—58
Castration-resistant prostatic neoplasmsD064129——252——8
Male breast neoplasmsD018567——115—17
CarcinomaD002277—C80.0231—17
Female infertilityD007247EFO_0008560N971—1—35
Neoplasm metastasisD009362EFO_0009708——32——4
Alzheimer diseaseD000544EFO_0000249F03—31——4
Pelvic painD017699———11——2
Show 19 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypogonadismD007006—E23.0—2——35
Salivary gland neoplasmsD012468EFO_0003826D11—4——15
HypersensitivityD006967EFO_0003785T78.40—4———4
Non-hodgkin lymphomaD008228—C85.9—3———3
Multiple myelomaD009101—C90.0—3———3
Endocrine system diseasesD004700EFO_0001379E34.9—2——13
Healthy volunteers/patients———31———3
Primary ovarian insufficiencyD016649EFO_0004266E28.3—1——23
Premature menopauseD008594—E28.31—1——23
Ovarian neoplasmsD010051EFO_0003893C5613———3
Show 51 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OverweightD050177—E66.31————1
Acquired immunodeficiency syndromeD000163EFO_0000765B201————1
Antibiotic prophylaxisD019072——1————1
TransgenesD019076——1————1
Postmenopausal osteoporosisD015663EFO_0003854—1————1
Delayed pubertyD011628—E30.01————1
Menstruation disturbancesD008599—N91.51————1
Premenstrual syndromeD011293—N94.31————1
Paraphilic disordersD010262—F651————1
Postoperative painD010149—G89.181————1
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gender dysphoriaD000068116—F64————33
Cardiovascular diseasesD002318EFO_0000319I98————22
AdiposityD050154——————11
Embryo implantationD010064——————11
Executive functionD056344——————11
Coronary diseaseD003327——————11
MicrobiotaD064307——————11
HemangiomaD006391—D18.0————11
Bone developmentD001846——————11
PubertyD011627EFO_0001382—————11
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
No data
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
7,717 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use